Pexidartinib在健康受试者中基于吸收和代谢的药物相互作用潜力评估
本文通过四项开放标签交叉研究评估pH调节剂、强CYP3A4抑制剂、强CYP3A/UGT诱导剂和UGT抑制剂对pexidartinib单剂药代动力学的影响,并建立生理药代动力学模型预测中等CYP3A4抑制剂和诱导剂的作用。结果显示联合用药可显著改变pexidartinib暴露,为临床剂量调整提供依据。
要点
- 强CYP3A4抑制剂增加pexidartinib暴露,强诱导剂降低暴露。
- 质子泵抑制剂降低pexidartinib暴露,可能因溶解度下降。
- UGT抑制剂增加pexidartinib暴露,与其经UGT1A4代谢一致。
核心结论
- 强CYP3A4抑制剂伊曲康唑增加pexidartinib暴露,强CYP3A/UGT诱导剂利福平降低暴露。
- 质子泵抑制剂埃索美拉唑降低pexidartinib暴露,UGT抑制剂丙磺舒增加暴露。
- 生理药代动力学模型预测中等CYP3A4抑制剂和诱导剂分别 modestly 增加和降低pexidartinib暴露。
- 结果可为pexidartinib与具有药物相互作用潜力的药物联用时的剂量建议提供依据。
研究设计与样本
- 四项开放标签交叉研究评估pH调节剂、强CYP3A4抑制剂、强CYP3A/UGT诱导剂和UGT抑制剂对pexidartinib单剂药代动力学的影响。
- 建立生理药代动力学模型预测中等CYP3A4抑制剂和中等CYP3A诱导剂对pexidartinib药代动力学的影响。
主要发现
- 埃索美拉唑使pexidartinib的Cmax几何均值比(90%CI)为45.4%(36.8-55.9),AUC∞几何均值比(90%CI)为53.1%(47.4-59.3)。
- 伊曲康唑使pexidartinib的Cmax几何均值比(90%CI)为148.3%(127.8-172.0),AUC∞几何均值比(90%CI)为173.0%(160.7-186.3)。
- 利福平使pexidartinib的Cmax几何均值比(90%CI)为67.1%(53.1-84.8),AUC∞几何均值比(90%CI)为37.0%(30.6-44.8)。
- 丙磺舒使pexidartinib的Cmax几何均值比(90%CI)为105.8%(92.4-121.0),AUC∞几何均值比(90%CI)为159.8%(143.4-178.0)。
- 生理药代动力学模型预测中等CYP3A4抑制剂和中等CYP3A诱导剂分别 modestly 增加和降低pexidartinib暴露。
关键数值与推荐
- pexidartinib是UGT1A4底物,UGT1A4负责生成主要代谢物ZAAD-1006a。
临床怎么用
- 当pexidartinib与具有药物相互作用潜力的药物联用时,可依据本研究结果进行剂量调整。
- 无法避免联用时,应考虑调整pexidartinib剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Pexidartinib is a novel oral small-molecule inhibitor that selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation. It is approved in the United States for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Pexidartinib in vitro data indicate the potential for absorption- and metabolism-related drug-drug interactions (DDIs). The objective was to present a comprehensive DDI risk assessment of agents that can impact pexidartinib exposure by altering its absorption and metabolism potentially affecting efficacy and safety of pexidartinib. METHODS: Four open-label crossover studies were performed to assess the effects of a pH modifier (esomeprazole), a strong cytochrome P450 (CYP) 3A4 inhibitor (itraconazole), a strong CYP3A/5'-diphospho-glucuronosyltransferase (UGT) inducer (rifampin), and a UGT inhibitor (probenecid) on the single-dose pharmacokinetics of pexidartinib. In addition, a physiologically based pharmacokinetic model was developed to predict the effect of a moderate CYP3A4 inhibitor (fluconazole) and a moderate CYP3A inducer (efavirenz) on the pharmacokinetics of pexidartinib. RESULTS: Co-administration of pexidartinib with esomeprazole modestly decreased pexidartinib exposure (maximum plasma concentration [Cmax], ng/mL: geometric mean ratio [90% confidence interval (CI)], 45.4% [36.8-55.9]; area under the drug plasma concentration-time curve from time 0 to infinity [AUC∞], ng•h/mL: geometric mean ratio [90% CI], 53.1% [47.4-59.3]), likely related to decreased solubility of pexidartinib at increased pH levels. As expected, the strong CYP3A4 inhibitor itraconazole increased pexidartinib exposure (Cmax, ng/mL: geometric mean ratio [90% CI], 148.3% [127.8-172.0]; AUC∞, ng•h/mL: geometric mean ratio [90% CI], 173.0% [160.7-186.3]) while the strong CYP3A/UGT inducer rifampin decreased exposure (Cmax, ng/mL: geometric mean ratio [90% CI], 67.1% [53.1-84.8]; AUC∞, ng•h/mL: geometric mean ratio [90% CI], 37.0% [30.6-44.8]). In addition, UGT inhibition increased pexidartinib exposure (Cmax, ng/mL: geometric mean ratio [90% CI], 105.8% [92.4-121.0]; AUC∞, ng•h/mL: geometric mean ratio [90% CI], 159.8% [143.4-178.0]), consistent with the fact that pexidartinib is a substrate of the UGT1A4 enzyme, which is responsible for the generation of the major metabolite, ZAAD-1006a. CONCLUSIONS: The physiologically based pharmacokinetic model predicted that a moderate CYP3A4 inhibitor and a moderate CYP3A inducer would produce modest increases and decreases, respectively, in pexidartinib exposure. These results provide a basis for pexidartinib dosing recommendations when administered concomitantly with drugs with drug-drug interaction potential, including dose adjustments when concomitant administration cannot be avoided. CLINICAL TRIAL REGISTRATION: Probenecid: phase I trial, NCT03138759, 3 May, 2017; esomeprazole, itraconazole, rifampin: phase I trials, not registered with ClinicalTrials.gov.
引用
- Zahir H, Greenberg J, Shuster D, et al. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects. Clin Pharmacokinet. 2022. PMID: 36264536. doi:10.1007/s40262-022-01172-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。